好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Postherpetic pruritus successfully treated with Onabotulinum toxin: A case report
Infectious Disease
P12 - Poster Session 12 (5:30 PM-6:30 PM)
13-003
Postherpetic pruritus is an underreported but significant sequelae of Herpes zoster infection. It can present isolated or in conjunction with postherpetic neuralgia. 
A 78-year-old woman who presented with Shingles in V1 dermatome distribution of the left trigeminal nerve developed postherpetic neuralgia and pruritus. Standard treatment with antivirals resolved the pain but the postherpetic itching persisted. Trials of antidepressant and nerve pain medications such as Duloxetine and Doxepin couldn’t alleviate the symptoms or were not tolerated. Topical corticosteroid cream provided the only relief at the time. However, it induced profound skin thinning. 
Due to concomitant blepharospasm, the patient was injected with a pattern Onabotulinum toxin targeting the blepharospasm and additional units were added in the areas of pruritus on the scalp and forehead. 
The result was complete resolution of blepharospasm and dramatic improvement of the itching. The symptoms reoccurred a few months later and subsequent treatments with Onabotulinum toxin were performed, and consistently had notable improvement. The only side effect was post injection bruising after the initial injections which subsided rapidly in the days following. 

In conclusion, Botulinum toxin administration might constitute a valuable option for symptomatic relief of postherpetic itching, especially after the failure of first-choice treatment.
Authors/Disclosures
Juliana Stoilova, MD
PRESENTER 		Ms. Stoilova has nothing to disclose.
Rebekah G. Torres, NP (Neurology & Pain Speciality Center) Mrs. Torres has received personal compensation in the range of $0-$499 for serving as a Panelist with IQVIA.
Kenneth P. Martinez, MD (Neurology & Pain Specialty Center) The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. The institution of Dr. Martinez has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Revance. The institution of Dr. Martinez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie/Allergan. The institution of Dr. Martinez has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Merz. The institution of Dr. Martinez has received research support from Medtronic. The institution of Dr. Martinez has received research support from Abbvie/Allergan.